Page last updated: 2024-12-09

4-hydroxyisoleucine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2773624
CHEMBL ID4101687
CHEBI ID180593
SCHEMBL ID52746
MeSH IDM0273304

Synonyms (37)

Synonym
AC-6053
4-hydroxy-l-isoleucine ,
(2s,3r)-2-amino-4-hydroxy-3-methylpentanoic acid
CHEBI:180593
4-hydroxy isoleucine
AKOS005255263
l-4-hydroxyisoleucine
781658-23-9
4-hydroxyisoleucine
S9062
AKOS015855988
OSCCDBFHNMXNME-DSDZBIDZSA-N
SCHEMBL52746
4-hydoxy-l-isoleucine
mfcd06799350
W-203089
Q-100695
(2s,3r,4s)hydroxy isoleucine
4-hydroxy-l-isoleucine, >=98.0% (tlc)
4-hydroxyisoleucine, united states pharmacopeia (usp) reference standard
(2s,3r)-2-amino-4-hydroxy-3-methylpentanoic acid (non-preferred name)
STL554524
BBL100730
MS-20746
CS-W016348
HY-N6858
CCG-266183
CHEMBL4101687
D97437
4-?hydroxy-?l-?isoleucine
AC-36705
4-ydroxy--soleucine
A865086
PD087952
DTXSID101347038
90639-06-8
rel-(2s,3r)-2-amino-4-hydroxy-3-methylpentanoic acid

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" This investigation shows that the absorption rate increased, whereas distribution and elimination processes slowed down in diabetic rats compared with normal rats."( A novel UPLC-MS/MS method for simultaneous quantification of trigonelline, 4-hydroxyisoleucine, and diosgenin from Trigonella foenum-graecum extract: Application to pharmacokinetic study in healthy and type 2 diabetic rats.
Banerjee, D; Dubey, SK; Katiyar, C; Krishna, KV; Narwaria, A; Taliyan, R; Tandon, N; Wadhwa, G; Yadav, SS, 2022
)
0.95
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
isoleucine derivativeAn amino acid derivative resulting from reaction of isoleucine at the amino group or the carboxy group, or from the replacement of any hydrogen of isoleucine by a heteroatom. The definition normally excludes peptides containing isoleucine residues.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (5.77)18.2507
2000's12 (23.08)29.6817
2010's26 (50.00)24.3611
2020's11 (21.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.53 (24.57)
Research Supply Index3.97 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index39.83 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (9.62%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other47 (90.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]